Literature DB >> 16170536

Neuroendocrine tumours metastatic to the uvea: diagnosis by fine needle aspiration biopsy.

Nikolaos Trichopoulos1, James J Augsburger.   

Abstract

BACKGROUND: Uveal metastasis from a neuroendocrine tumour is rare and can simulate other primary or metastatic uveal tumours, both clinically and cytomorphologically. We describe four cases of uveal metastasis from a neuroendocrine tumour diagnosed by fine needle aspiration biopsy (FNAB).
METHODS: Four patients were referred for evaluation of a recently detected fundus mass. Two patients had a history of malignant, non-ocular, neuroendocrine neoplasms (Merkel cell carcinoma and lung carcinoid in one patient each). The third patient had a mediastinal mass that had been biopsied inconclusively, while the last patient reported a persistent cough.
RESULTS: Ophthalmic examination revealed an amelanotic ciliochoroidal mass in 2 cases and a lightly melanotic and a pale orange choroidal mass in 1 case each. Partial, non-rhegmatogenous, retinal detachment was present in 3 patients. Ocular ultrasonography revealed moderate to high internal reflectivity of the mass in 3 cases and low internal reflectivity in the 4th. Our differential diagnosis in all cases was metastatic carcinoma versus primary uveal melanoma. FNAB of the intraocular mass was performed in all patients to establish a pathologic diagnosis and guide subsequent management. Cytomorphology and immunohistochemical profiles of the aspirates were consistent with metastatic neuroendocrine neoplasms in all patients. Our final diagnosis was metastatic lung carcinoid in 2 patients and metastatic Merkel cell carcinoma and small cell lung carcinoma in 1 patient each. Immediately after FNAB, the intraocular tumour was treated by plaque radiotherapy (3 patients) or fractionated external beam radiotherapy (1 patient). All tumours treated regressed satisfactorily. Two patients expired due to widespread lung carcinoid 11 and 12 months after our initial evaluation respectively. The other two patients are still alive after 38 and 64 months respectively.
CONCLUSIONS: Neuroendocrine tumours are a heterogeneous group of neoplasms whose diagnosis ultimately depends on the identification of specific cell markers (e.g., neuron-specific enolase, chromogranin, synaptophysin), hormones and neurotransmitters (e.g., gastrin, serotonin, adrenocorticotrophic hormone [ACTH]). FNAB with immunohistochemical stains for neuroendocrine markers can establish a pathologic diagnosis in cases of uveal metastasis from a neuroendocrine tumour. To our knowledge, our patient with Merkel cell carcinoma is the first pathologically proven case of uveal metastasis from this primary malignancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170536     DOI: 10.1007/s00417-005-0113-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  10 in total

1.  Presumed choroidal metastasis of Merkel cell carcinoma.

Authors:  K W Small; G O Rosenwasser; E Alexander; G Rossitch; J J Dutton
Journal:  Ann Ophthalmol       Date:  1990-05

2.  A choroidal amyloid-rich neuroendocrine tumor: initial manifestation of Cushing syndrome.

Authors:  S O Brannan; N G Lessan; P Hiscott; B Damato
Journal:  Arch Ophthalmol       Date:  1999-08

Review 3.  Immunohistology of neuroendocrine and neuroectodermal tumors.

Authors:  M R Wick
Journal:  Semin Diagn Pathol       Date:  2000-08       Impact factor: 3.464

4.  Choroidal metastasis as the initial manifestation of a pigmented neuroendocrine tumor.

Authors:  R C Eagle; H Ehya; J A Shields; C L Shields
Journal:  Arch Ophthalmol       Date:  2000-06

5.  Merkel cell carcinoma. Long term survival in a patient with proven brain metastasis and presumed choroid metastasis.

Authors:  E Alexander; E Rossitch; K Small; G O Rosenwasser; P Abson
Journal:  Clin Neurol Neurosurg       Date:  1989       Impact factor: 1.876

6.  Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category.

Authors:  James J Augsburger; Zélia M Corrêa; Susan Schneider; Rawia S Yassin; Toni Robinson-Smith; Hormoz Ehya; Nikolaos Trichopoulos
Journal:  Trans Am Ophthalmol Soc       Date:  2002

7.  Clinical features and treatment of seven patients with carcinoid tumor metastatic to the eye and orbit.

Authors:  J T Fan; H Buettner; G B Bartley; J P Bolling
Journal:  Am J Ophthalmol       Date:  1995-02       Impact factor: 5.258

8.  Fine needle aspiration biopsy of suspected metastatic cancers to the posterior uvea.

Authors:  J J Augsburger
Journal:  Trans Am Ophthalmol Soc       Date:  1988

Review 9.  Uveal metastasis from carcinoid tumor. Clinical observations in nine cases.

Authors:  J W Harbour; P De Potter; C L Shields; J A Shields
Journal:  Ophthalmology       Date:  1994-06       Impact factor: 12.079

Review 10.  Medical treatment of neuroendocrine tumors.

Authors:  E Bajetta; M Di Bartolomeo; N Zilembo; A M Bochicchio
Journal:  Tumori       Date:  1993-12-31
  10 in total
  4 in total

1.  Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for PHF10/BAF45a.

Authors:  Hima Anbunathan; Ruth Verstraten; Arun D Singh; J William Harbour; Anne M Bowcock
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

2.  Fine needle aspiration biopsy of ophthalmic tumors.

Authors:  Arun D Singh; Charles V Biscotti
Journal:  Saudi J Ophthalmol       Date:  2012-04

3.  Instrument Gauge and Type in Uveal Melanoma Fine Needle Biopsy: Implications for Diagnostic Yield and Molecular Prognostication.

Authors:  Lindsay K Klofas; Carley M Bogan; Alice C Coogan; Stephen J Schultenover; Vivian L Weiss; Anthony B Daniels
Journal:  Am J Ophthalmol       Date:  2020-08-18       Impact factor: 5.258

4.  Unusual orange-colored choroidal metastases.

Authors:  Hatem Krema; Hugh McGowan; Herbert Tanzer; Rand Simpson; Normand Laperriere
Journal:  J Ophthalmic Vis Res       Date:  2013-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.